New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
06:42 EDTRVNCRevance risk not heightened from FDA guidance, says Piper Jaffray
Piper Jaffray does not see heightened risk around Revance's RT001 after the FDA issued draft guidance on clinical endpoints for botulinum toxin products for the treatment of upper facial lines. The firm reiterates an Overweight rating on the stock with a $44 price target.
News For RVNC From The Last 14 Days
Check below for free stories on RVNC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for RVNC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use